Difference between revisions of "Template:Estrogen dosages for prostate cancer"

From blackwiki
Jump to navigation Jump to search
imported>Boghog
(tweak cites)
imported>Monkbot
m (→‎top: Task 17 (BRFA trial): replace / delete to-be-deprecated: |name-list-format= (3× replaced; 1× deleted; usage: 3 of 4);)
Line 6: Line 6:
 
| rowspan="11" | [[Oral administration|Oral]] || {{No selflink|Estradiol (medication)|Estradiol}} || 1–2 mg 3x/day <noinclude> || <ref name="Estrace-FDA-Label-2005">{{cite web | title = ESTRACE TABLETS (estradiol tablets, USP)| url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | work = Warner Chilott | publisher = U.S. Food and Drug Administration }}</ref></noinclude>
 
| rowspan="11" | [[Oral administration|Oral]] || {{No selflink|Estradiol (medication)|Estradiol}} || 1–2 mg 3x/day <noinclude> || <ref name="Estrace-FDA-Label-2005">{{cite web | title = ESTRACE TABLETS (estradiol tablets, USP)| url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | work = Warner Chilott | publisher = U.S. Food and Drug Administration }}</ref></noinclude>
 
|-
 
|-
−
| {{No selflink|Conjugated estrogens}} || 1.25–2.5 mg 3x/day <noinclude> || <ref name="ThomasKeenan1986">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J. | name-list-format = vanc |chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|chapter-url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref><ref name="Oettel1999">{{cite book| vauthors = Oettel M |chapter=Estrogens and Antiestrogens in the Male|pages=505–571|doi=10.1007/978-3-642-60107-1_25| veditors = Oettel M, Schillinger E |title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|series=Handbook of Experimental Pharmacology|chapter-url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA538|date=1999|volume=135 / 2|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|issn=0171-2004}}</ref></noinclude>
+
| {{No selflink|Conjugated estrogens}} || 1.25–2.5 mg 3x/day <noinclude> || <ref name="ThomasKeenan1986">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J. | name-list-style = vanc |chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|chapter-url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref><ref name="Oettel1999">{{cite book| vauthors = Oettel M |chapter=Estrogens and Antiestrogens in the Male|pages=505–571|doi=10.1007/978-3-642-60107-1_25| veditors = Oettel M, Schillinger E |title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|series=Handbook of Experimental Pharmacology|chapter-url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA538|date=1999|volume=135 / 2|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|issn=0171-2004}}</ref></noinclude>
 
|-
 
|-
 
| {{No selflink|Ethinylestradiol}} || 0.15–3 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="Oettel1999" /><ref name="Martz2013">{{cite book| vauthors = Martz G |title=Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms|url=https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA51|date=13 March 2013|publisher=Springer-Verlag|isbn=978-3-642-86282-3|pages=51–}}</ref></noinclude>
 
| {{No selflink|Ethinylestradiol}} || 0.15–3 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="Oettel1999" /><ref name="Martz2013">{{cite book| vauthors = Martz G |title=Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms|url=https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA51|date=13 March 2013|publisher=Springer-Verlag|isbn=978-3-642-86282-3|pages=51–}}</ref></noinclude>
Line 12: Line 12:
 
| {{No selflink|Ethinylestradiol sulfonate}} || 1–2 mg 1x/week <noinclude> || <ref name="HöflingHeynemann2014">{{cite journal| vauthors = Höfling G, Heynemann H |title=Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?|trans-title=Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?|journal=Der Urologe B|volume=38|issue=2|year=2014|pages=165–170|issn=0042-1111|doi=10.1007/s001310050185}}</ref><ref name="Oettel1999" /><ref name="HinkelbeinMiller2013">{{cite book|author1=Wolfgang Hinkelbein|author2=Kurt Miller|author3=Thomas Wiegel|title=Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte|url=https://books.google.com/books?id=wdTLBgAAQBAJ&pg=PA91|date=7 March 2013|publisher=Springer-Verlag|isbn=978-3-642-60064-7|pages=91–}}</ref></noinclude>
 
| {{No selflink|Ethinylestradiol sulfonate}} || 1–2 mg 1x/week <noinclude> || <ref name="HöflingHeynemann2014">{{cite journal| vauthors = Höfling G, Heynemann H |title=Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?|trans-title=Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?|journal=Der Urologe B|volume=38|issue=2|year=2014|pages=165–170|issn=0042-1111|doi=10.1007/s001310050185}}</ref><ref name="Oettel1999" /><ref name="HinkelbeinMiller2013">{{cite book|author1=Wolfgang Hinkelbein|author2=Kurt Miller|author3=Thomas Wiegel|title=Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte|url=https://books.google.com/books?id=wdTLBgAAQBAJ&pg=PA91|date=7 March 2013|publisher=Springer-Verlag|isbn=978-3-642-60064-7|pages=91–}}</ref></noinclude>
 
|-
 
|-
−
| {{No selflink|Diethylstilbestrol}} || 1–3 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="Lupulescu1990">{{cite book| first = Aurel | last = Lupulescu | name-list-format = vanc |chapter=Hormones and Hormonotherapy|title=Hormones and Vitamins in Cancer Treatment|chapter-url=https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57|date=24 October 1990|publisher=CRC Press|isbn=978-0-8493-5973-6|pages=33–90}}</ref></noinclude>
+
| {{No selflink|Diethylstilbestrol}} || 1–3 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="Lupulescu1990">{{cite book| first = Aurel | last = Lupulescu | name-list-style = vanc |chapter=Hormones and Hormonotherapy|title=Hormones and Vitamins in Cancer Treatment|chapter-url=https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57|date=24 October 1990|publisher=CRC Press|isbn=978-0-8493-5973-6|pages=33–90}}</ref></noinclude>
 
|-
 
|-
 
| {{No selflink|Dienestrol}} || 5 mg/day <noinclude> || <ref name="JacobiHohenfellner1982">{{cite book|author1=Günther H. Jacobi|author2=Rudolf Hohenfellner|title=Prostate Cancer|url=https://books.google.com/books?id=4HNrAAAAMAAJ|date=1 December 1982|publisher=Williams & Wilkins|isbn=978-0-683-04354-9|page=223}}</ref></noinclude>
 
| {{No selflink|Dienestrol}} || 5 mg/day <noinclude> || <ref name="JacobiHohenfellner1982">{{cite book|author1=Günther H. Jacobi|author2=Rudolf Hohenfellner|title=Prostate Cancer|url=https://books.google.com/books?id=4HNrAAAAMAAJ|date=1 December 1982|publisher=Williams & Wilkins|isbn=978-0-683-04354-9|page=223}}</ref></noinclude>
Line 18: Line 18:
 
| {{No selflink|Hexestrol}} || 5 mg/day <noinclude> || <ref name="JacobiHohenfellner1982" /></noinclude>
 
| {{No selflink|Hexestrol}} || 5 mg/day <noinclude> || <ref name="JacobiHohenfellner1982" /></noinclude>
 
|-
 
|-
−
| {{No selflink|Fosfestrol}} || 100–480 mg 1–3x/day <noinclude> || <ref name="Martindale-Fosfestrol">{{cite book | veditors = Sweetman SC |chapter=Sex hormones and their modulators |title=Martindale: The Complete Drug Reference |edition=36th |year=2009 |page=2104–2105 |publisher=Pharmaceutical Press |location=London|isbn=978-0-85369-840-1|url=https://www.medicinescomplete.com/mc/martindale/}}</ref><ref name="BruchhausenDannhardt2013">{{cite book |first1 = Franz | last1 = von Bruchhausen| first2 = Gerd | last2 = Dannhardt | first3 = Siegfried | last3 = Ebel | first4 = August W. | last4 = Frahm | first5 = Eberhard | last5 = Hackenthal | first6 = Ulrike | last6 = Holzgrabe | name-list-format = vanc |title=Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O|url=https://books.google.com/books?id=8vSjBgAAQBAJ&pg=PA301|date=2 July 2013|publisher=Springer-Verlag|isbn=978-3-642-57994-3|pages=301–}}</ref><ref name="Martz2013" /></noinclude>
+
| {{No selflink|Fosfestrol}} || 100–480 mg 1–3x/day <noinclude> || <ref name="Martindale-Fosfestrol">{{cite book | veditors = Sweetman SC |chapter=Sex hormones and their modulators |title=Martindale: The Complete Drug Reference |edition=36th |year=2009 |page=2104–2105 |publisher=Pharmaceutical Press |location=London|isbn=978-0-85369-840-1|url=https://www.medicinescomplete.com/mc/martindale/}}</ref><ref name="BruchhausenDannhardt2013">{{cite book |first1 = Franz | last1 = von Bruchhausen| first2 = Gerd | last2 = Dannhardt | first3 = Siegfried | last3 = Ebel | first4 = August W. | last4 = Frahm | first5 = Eberhard | last5 = Hackenthal | first6 = Ulrike | last6 = Holzgrabe | name-list-style = vanc |title=Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O|url=https://books.google.com/books?id=8vSjBgAAQBAJ&pg=PA301|date=2 July 2013|publisher=Springer-Verlag|isbn=978-3-642-57994-3|pages=301–}}</ref><ref name="Martz2013" /></noinclude>
 
|-
 
|-
−
| {{No selflink|Chlorotrianisene}} || 12–48 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="JacobiHohenfellner1982" /><ref name="Dao1975">{{cite book | last1 = Dao | first1 = Thomas L. | name-list-format = vanc | chapter = Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms | year = 1975 | pages = 170–192 | doi = 10.1007/978-3-642-65806-8_11 | veditors = Sartorelli AC, Johns DG | title = Antineoplastic and Immunosuppressive Agents | chapter-url = https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170 | isbn = 978-3-642-65806-8}}</ref><ref name="Martz2013" /></noinclude>
+
| {{No selflink|Chlorotrianisene}} || 12–48 mg/day <noinclude> || <ref name="ThomasKeenan1986" /><ref name="JacobiHohenfellner1982" /><ref name="Dao1975">{{cite book | last1 = Dao | first1 = Thomas L. | chapter = Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms | year = 1975 | pages = 170–192 | doi = 10.1007/978-3-642-65806-8_11 | veditors = Sartorelli AC, Johns DG | title = Antineoplastic and Immunosuppressive Agents | chapter-url = https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170 | isbn = 978-3-642-65806-8}}</ref><ref name="Martz2013" /></noinclude>
 
|-
 
|-
 
| {{No selflink|Quadrosilan}} || 900 mg/day <noinclude> || <ref name="JacobiHohenfellner1982" /></noinclude>
 
| {{No selflink|Quadrosilan}} || 900 mg/day <noinclude> || <ref name="JacobiHohenfellner1982" /></noinclude>

Revision as of 07:34, 20 October 2020

Estrogen dosages for prostate cancer

Route/form Estrogen Dosage Ref(s)
Oral Template:No selflink 1–2 mg 3x/day [1]
Template:No selflink 1.25–2.5 mg 3x/day [2][3]
Template:No selflink 0.15–3 mg/day [2][3][4]
Template:No selflink 1–2 mg 1x/week [5][3][6]
Template:No selflink 1–3 mg/day [2][7]
Template:No selflink 5 mg/day [8]
Template:No selflink 5 mg/day [8]
Template:No selflink 100–480 mg 1–3x/day [9][10][4]
Template:No selflink 12–48 mg/day [2][8][11][4]
Template:No selflink 900 mg/day [8]
Template:No selflink 140–1400 mg/day [12]
Transdermal patch Template:No selflink 2–6x 100 μg/day
Scrotal: 1x 100 μg/day		 [13][14]
[15]
IM or SC injection Template:No selflink 1.66 mg 3x/week [16]
Template:No selflink 5 mg 1x/week [16]
Template:No selflink 10–40 mg 1x/1–2 weeks [17][18]
Template:No selflink 100 mg 1x/4 weeks [19][8]
Template:No selflink Alone: 160–320 mg 1x/4 weeks
With oral EE: 40–80 mg 1x/4 weeks		 [20][19]
[21][8]
Template:No selflink 2–4 mg 2–3x/week [2][22]
IV injection Template:No selflink 300–1200 mg 1–7x/week [9][10][4]
Template:No selflink 240–450 mg/day [12][23]
Note: Dosages are not necessarily equivalent.
50px Template documentation

See also

References

  1. ↑ "ESTRACE TABLETS (estradiol tablets, USP)" (PDF). Warner Chilott. U.S. Food and Drug Administration.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1. Unknown parameter |name-list-style= ignored (help)
  3. ↑ 3.0 3.1 3.2 Oettel M (1999). "Estrogens and Antiestrogens in the Male". In Oettel M, Schillinger E (eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Handbook of Experimental Pharmacology. 135 / 2. Springer Science & Business Media. pp. 505–571. doi:10.1007/978-3-642-60107-1_25. ISBN 978-3-642-60107-1. ISSN 0171-2004.
  4. ↑ 4.0 4.1 4.2 4.3 Martz G (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 51–. ISBN 978-3-642-86282-3.
  5. ↑ Höfling G, Heynemann H (2014). "Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?" [Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?]. Der Urologe B. 38 (2): 165–170. doi:10.1007/s001310050185. ISSN 0042-1111.
  6. ↑ Wolfgang Hinkelbein; Kurt Miller; Thomas Wiegel (7 March 2013). Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte. Springer-Verlag. pp. 91–. ISBN 978-3-642-60064-7.
  7. ↑ Lupulescu, Aurel (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6. Unknown parameter |name-list-style= ignored (help)
  8. ↑ 8.0 8.1 8.2 8.3 8.4 8.5 Günther H. Jacobi; Rudolf Hohenfellner (1 December 1982). Prostate Cancer. Williams & Wilkins. p. 223. ISBN 978-0-683-04354-9.
  9. ↑ 9.0 9.1 Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2104–2105. ISBN 978-0-85369-840-1.
  10. ↑ 10.0 10.1 von Bruchhausen, Franz; Dannhardt, Gerd; Ebel, Siegfried; Frahm, August W.; Hackenthal, Eberhard; Holzgrabe, Ulrike (2 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O. Springer-Verlag. pp. 301–. ISBN 978-3-642-57994-3. Unknown parameter |name-list-style= ignored (help)
  11. ↑ Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
  12. ↑ 12.0 12.1 Perry CM, McTavish D (July 1995). "Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". Drugs & Aging. 7 (1): 49–74. doi:10.2165/00002512-199507010-00006. PMID 7579781. S2CID 36725810.
  13. ↑ Ockrim J, Lalani JL, Abel P (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nature Clinical Practice. Oncology. 3 (10): 552–63. doi:10.1038/ncponc0602. PMID 17019433. S2CID 6847203.
  14. ↑ Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (May 2003). "Transdermal estradiol therapy for advanced prostate cancer--forward to the past?". The Journal of Urology. 169 (5): 1735–7. doi:10.1097/01.ju.0000061024.75334.40. PMID 12686820.
  15. ↑ Re I, Asenjo G, Maximino G, Micheletti L (2005). "Tratamiento del Cáncer de Próstata Avanzado con Estrógenos Transdérmicos Escrotales (ETE)" [Transdermal Scrotal Estrogen Patches (TSEP) in the Treatment of Advanced Prostate Cancer]. Revista Argentina de Urología (in Spanish). 70 (4): 231. ISSN 0325-2531.
  16. ↑ 16.0 16.1 "NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 10 (11): 692–694. 1949. doi:10.1016/S0095-9561(16)31995-8. ISSN 0095-9561.
  17. ↑ "DELESTROGEN (estradiol valerate injection, USP)" (PDF). Par Pharmaceutical, Inc. U.S. Food and Drug Administration.
  18. ↑ Kohli M, Alikhan MA, Spencer HJ, Carter G (2004). "Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer". Journal of Clinical Oncology. 22 (14_suppl): 4726. doi:10.1200/jco.2004.22.90140.4726. ISSN 0732-183X.
  19. ↑ 19.0 19.1 Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, et al. (February 2008). "Parenteral oestrogen in the treatment of prostate cancer: a systematic review". British Journal of Cancer. 98 (4): 697–707. doi:10.1038/sj.bjc.6604230. PMC 2259178. PMID 18268497.
  20. ↑ "Estradurin Polyestradiol Phosphate". Pharmanovia. Archived from the original on 20 June 2016.
  21. ↑ Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". The Journal of Urology. 154 (6): 1991–8. doi:10.1016/s0022-5347(01)66670-9. PMID 7500443.
  22. ↑ "Estrone suspension approval" (PDF). Center for Drug Evaluation and Research. U.S. Food and Drug Administration.
  23. ↑ Bergenheim AT, Henriksson R (February 1998). "Pharmacokinetics and pharmacodynamics of estramustine phosphate". Clinical Pharmacokinetics. 34 (2): 163–72. doi:10.2165/00003088-199834020-00004. PMID 9515186. S2CID 1943973.
Retrieved from "https://blackwiki.org/index.php?title=Template:Estrogen_dosages_for_prostate_cancer&oldid=4888031"